FDA Warns Companies Over Misleading Claims of GLP-1 Copycats (opens in new tab)

The US Food and Drug Administration issued 25 warning letters to telehealth companies for marketing false and misleading claims about compounded GLP-1s, cracking down on several businesses selling copycat weight loss and diabetes drugs.